OPHN1 and posterior cortical atrophy: To link our above studies to potential clinical applications, we were interested in applying small molecule(s) to target this newly identified lnc-OPHN1-5/AR/hnRNPA1 complex to increase the Enz treatment sensitivity, thus better suppress the PCa progression.